Krystal Biotech to Present at the American Thoracic Society 2024 International Conference
15. Mai 2024 07:00 ET
|
Krystal Biotech, Inc.
PITTSBURGH, May 15, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, announced today that the Company will be presenting new...
Krystal Biotech to Present at BofA Securities 2024 Health Care Conference
08. Mai 2024 07:00 ET
|
Krystal Biotech, Inc.
PITTSBURGH, May 08, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that the Company will participate in the...
Krystal Biotech Announces First Quarter 2024 Financial Results and Provides Business Updates
06. Mai 2024 08:00 ET
|
Krystal Biotech, Inc.
Net product revenue of $45.3 million in 1Q and $95.9 million since AugustFirst patient dosed in inhaled KB707 study for locally advanced or metastatic tumors of the lungReceived Fast Track...
Krystal Biotech to Present at the Association for Research in Vision and Ophthalmology 2024 Annual Meeting
02. Mai 2024 07:00 ET
|
Krystal Biotech, Inc.
PITTSBURGH, May 02, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, announced today that the Company will be presenting new...
Krystal Biotech to Report First Quarter 2024 Financial Results on May 6, 2024
26. April 2024 07:00 ET
|
Krystal Biotech, Inc.
PITTSBURGH, April 26, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that it will report its first quarter...
Krystal Biotech Announces First Patient Dosed in Phase 1 Clinical Trial of Inhaled KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors of the Lung
22. April 2024 07:00 ET
|
Krystal Biotech, Inc.
• Received Fast Track Designations for both inhaled and intratumoral KB707 PITTSBURGH, April 22, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage...
Krystal Biotech to Present at the American Association for Cancer Research 2024 Annual Meeting
04. April 2024 07:00 ET
|
Krystal Biotech, Inc.
PITTSBURGH, April 04, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, announced today that the Company will be presenting new...
Krystal Biotech to Present at TD Cowen 44th Annual Health Care Conference
28. Februar 2024 07:00 ET
|
Krystal Biotech, Inc.
PITTSBURGH, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that the Company will participate in the...
Krystal Biotech Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates
26. Februar 2024 08:00 ET
|
Krystal Biotech, Inc.
• Net product revenue of $42.1M in 4Q and $50.7M for the year • New England Journal of Medicine publication of the use of B-VEC eyedrop formulation • Reached alignment with FDA to enable...
Krystal Biotech to Report Fourth Quarter and Full Year 2023 Financial Results on February 26, 2024
20. Februar 2024 07:00 ET
|
Krystal Biotech, Inc.
PITTSBURGH, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, will report its fourth quarter and full year 2023...